Company news
Lakefront Biotherapeutics news in 2025
Lakefront Biotherapeutics's news releases, calls and decks from 2025, newest first.
Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus
December 18, 2025
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
December 8, 2025
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update
November 5, 2025
Galapagos to Present New Data from Cell Therapy Program at ASH 2025
November 3, 2025
Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development
October 30, 2025
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors
October 23, 2025
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation
October 21, 2025
Galapagos Announces Appointment of Fred Blakeslee as General Counsel
October 16, 2025
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business
October 1, 2025
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
August 6, 2025
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation
July 23, 2025
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors
July 23, 2025
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update
July 23, 2025
Galapagos Appoints Aaron Cox as Chief Financial Officer
June 23, 2025
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
June 18, 2025
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL
June 12, 2025
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101
May 14, 2025
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
May 13, 2025
Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts
April 23, 2025